IMNM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Mkt Cap

$1.94B

Volume

1.03M

Next Earnings

November 5th

Loading chart

IM

IMNMImmunome, Inc.

IMNM

Pay with—

Available Balance0.00

IM

Mkt Cap

$2.05B

Volume

1.03M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You MoreJack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares (30% of his direct holdings) for approximately $204,000 on April 2, 2026, through a pre-arranged Rule 10b5-1 trading plan established in December 2025. The sale represents routine financial diversification rather than a bearish signal, as Higgins maintains a substantial $480,000 direct position. The real catalyst for investors is Immunome's planned NDA submission for varegacestat in Q2 2026, following positive Phase 3 RINGSIDE trial results in December 2025.The Motley Fool · Apr 4, 2026

Evaluating Immunome: Insights From 4 Financial AnalystsIn the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Immunome is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Biren Amin Piper Sandler Announces Overweight $27.00 - Brian Cheng JP Morgan Announces Overweight $24.00 - Michael Schmidt Guggenheim Announces Buy $35.00 - David Nierengarten Wedbush Raises Outperform $33.00 $27.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunome. This offers insight ...Full story available on Benzinga.comBenzinga · May 31, 2024

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue EstimatesImmunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 14, 2024

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out forImmunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · Apr 26, 2024

New Strong Sell Stocks for April 4thIMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.Zacks Investment Research · Apr 4, 2024

Company News for Apr 2, 2024Companies In The News Are: SMTC, OXM, IMNM, GOOGL.Zacks Investment Research · Apr 2, 2024

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. On Wednesday, Fed Governor Christopher J. Waller spoke in opposition to an early interest rate cut, citing the still uncertain inflation path, and noted that his stance is shared by a robust share of the Fed board. Thursday saw an upward revision to the fourth-quarter U.S. gross domestic product, with the economy expanding by 3.4% on an annualized basis, exceeding the previously estimated 3.2%. Traders marginally scaled back their bets on a June rate cut scenario, now placing the likelihood at 64%, down from 70% on Wednesday, according to the CME Group’s FedWatch tool. While the S&P 500 and the Dow remained unchanged for the day, the Nasdaq 100 eased by 0.2%, influenced by reduced rate cut expectations and increasing commodity prices that weighed on tech companies. Gold surged to $2,225 per ounce intraday ...Full story available on Benzinga.comBenzinga · Mar 28, 2024

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On FridayU.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. (NYSE: WS) rose sharply during Friday’s session as the company posted stronger-than-expected results for its third quarter. Worthington Steel posted adjusted earnings of 99 cents per share, beating market estimates of 84 cents per share. The company’s quarterly sales came in at $805.80 million, versus expectations of $700.50 million, according to data from Benzinga Pro. Worthington Steel shares jumped 18.8% to $37.92 on Friday. Here are some other big stocks recording gains in today’s session. Murano Global Investments PLC (NASDAQ: MRNO) shares gained 147.5% to $23.94 after falling 46% on ...Benzinga · Mar 22, 2024

Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the 2021 highs. David Prince, professional trader at T3 Trading Group, joined Benzinga's “PreMarket Prep” on Tuesday and discussed the biotech industry, highlighting Viking Therapeutics, Inc. (NASDAQ:VKTX) and Immunome, Inc. (NASDAQ:IMNM) as notable recent movers. "I look for wherever I can make the most amount of money, legally, with the least amount of risk. Biotech into ‘24 was definitely one of those areas," Prince said. What To Know: Prince believes large biotech companies are looking to recapture growth while sitting on large amounts of capital. The professional trader expects these companies to find new growth opportunities through mergers, acquisitions and purchasing assets as ...Full story available on Benzinga.comBenzinga · Feb 28, 2024

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock UpImmunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.Zacks Investment Research · Feb 7, 2024

to start trading

IM

IMNMImmunome, Inc.

IMNM

Pay with—

Available Balance0.00

Your PositionYou don't own any IMNM yet.

Related Tickers

Earnings